What is IDX?
Founded in 2010, IDX is at the forefront of AI-driven medical diagnostics, aiming to make healthcare more accessible and affordable. The company specializes in creating clinically-aligned autonomous algorithms designed to detect diseases from medical images. By facilitating diagnostic assessments within primary care settings, IDX enhances patient access to high-quality, cost-effective disease detection. Its flagship product, IDx-DR, is an FDA-cleared system capable of identifying diabetic retinopathy and macular edema, with ongoing development for additional diagnostic systems targeting conditions like macular degeneration, glaucoma, and stroke risk.
How much funding has IDX raised?
IDX has raised a total of $40M across 4 funding rounds:
Private Equity
$1.4M
Private Equity
$1.1M
Private Equity
$4.5M
Series A
$33M
Private Equity (2012): $1.4M, investors not publicly disclosed
Private Equity (2012): $1.1M, investors not publicly disclosed
Private Equity (2013): $4.6M, investors not publicly disclosed
Series A (2018): $33M, investors not publicly disclosed
What's next for IDX?
The substantial enterprise-level backing and recent strategic investment indicate a strong growth trajectory for IDX. This capital infusion is likely to accelerate the development and deployment of its AI diagnostic solutions, potentially expanding its market reach and product portfolio. The company's focus on increasing access to diagnostics in primary care settings positions it to address critical gaps in healthcare delivery. Future endeavors may involve further regulatory approvals, strategic partnerships, and the scaling of its technology to impact a broader patient population.
See full IDX company page
